Patient-derived organoids as a predictive platform for drug sensitivity in bladder cancer.

Growing patient tumors in culture can predict which drugs will work, bringing precision medicine closer to the clinic.

Patient-derived organoid (PDO) cultures from bladder cancer specimens accurately recapitulate individual drug sensitivity profiles, demonstrating feasibility as a precision medicine platform to guide chemotherapy selection prior to systemic treatment initiation.

What the study was

Study design

translational

Category

precision_oncology

Maturity

translational

Journal

Scientific Reports

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.